X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Value assessments should include all the outcomes that matter to patients and families

By Katie Koziara  |    February 20, 2019
Value assessments are an important tool in moving toward better, more affordable health care. When it comes to assessing the value of medicines, we need approaches that reflect what matters to...   Read More

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

By Holly Campbell  |    February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...   Read More

Why vaccines work in the fight against measles and other infectious diseases

By Richard Moscicki, M.D.  |    February 13, 2019
It is often said that vaccines are only second to clean drinking water in terms of public health impact. In recent years, misinformation about vaccines, especially childhood vaccinations, has...   Read More

Combatting Opioid Abuse: Joint Partnership with the Rx Abuse Leadership Initiative and The National Sheriffs’ Association

By Priscilla VanderVeer  |    February 12, 2019
The National Sheriffs’ Association (NSA) recently partnered with the Rx Abuse Leadership Initiative (RALI), a dynamic alliance of organizations dedicated to finding solutions to the opioid crisis...   Read More

Biopharmaceutical venture capital is spurring innovation and economic growth

By Tim McClung  |    February 11, 2019
The biopharmaceutical ecosystem has helped make the U.S. the global leader in biomedical innovation today. An important part of this ecosystem is the thousands of small startup biopharmaceutical...   Read More

Why state drug importation pilot programs don’t work

By Nick McGee  |    February 8, 2019
Across the country, some states are recirculating failed proposals that would establish state-run prescription medicine importation schemes. Such proposals would allow medicines from foreign...   Read More

In survey, PhRMA member companies highlight impact of IPI on R&D

By Katie Verb  |    February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates